EXPE
88
2
CL
56
5
HON
65
-2
JWN
40
-2
NRG
49
-3
RSG
68
3
ETR
68
3
EQT
59
2
LB
34
8
HPE
55
11
PDCO
35
-3
EW
37
-2
AMP
69
-3
IP
70
2
JPM
63
-4
HSY
34
3
PSA
51
-4
T
50
3
COST
58
-2
BIIB
26
2
EXPE
88
2
CL
56
5
HON
65
-2
JWN
40
-2
NRG
49
-3
RSG
68
3
ETR
68
3
EQT
59
2
LB
34
8
HPE
55
11
PDCO
35
-3
EW
37
-2
AMP
69
-3
IP
70
2
JPM
63
-4
HSY
34
3
PSA
51
-4
T
50
3
COST
58
-2
BIIB
26
2
Financhill
Back

SpringWorks Therapeutics 10K Form

Buy
53

SWTX
SpringWorks Therapeutics

Last Price:
37.39
Seasonality Move:
51.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SWTX News And Ratings

See the #1 stock for the next 7 days that we like better than SWTX

SWTX Financial Statistics

Sales & Book Value

Annual Sales: $5.45M
Cash Flow: $-27.23M
Price / Cash Flow: 0
Annual Sales: $7.16
Price / Book: 4.83

Profitability

EPS (TTM): -3.89000
Net Income (TTM): $-275.16M
Gross Margin: $5.03M
Return on Equity: -51.38%
Return on Assets: -44.72%

SpringWorks Therapeutics Earnings Forecast

Key SpringWorks Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for SWTX is 92.25%.
  • The Selling, General & Administrative Expenses for SWTX have been equal to 3,626.79% of Gross Profit Margin.
  • The Research & Development expenses have been 2,762.75% of Revenue.
  • The Net Earning history of SWTX is -5,968.50% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

SpringWorks Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SWTX
CUSIP: 85205L
Website: springworkstx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.16
Quick Ratio: 5.8

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SWTX Technical Analysis vs Fundamental Analysis

Buy
53
SpringWorks Therapeutics (SWTX) is a Buy

Is SpringWorks Therapeutics a Buy or a Sell?